Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMTX705 with regorafenib and tislelizumab in advanced or metastatic colorectal cancer
2025-520743-33-00Phase 2Authorised
- Sponsor
- Oncomatryx
- Start
- Jul 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OMTX705, regorafenib and odronextamab in colorectal cancer (CRC), sponsored by Oncomatryx. Primary endpoints: Safety and tolerability, Clinical safety and dose finding and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
OMTX705regorafenibodronextamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-520743-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520743-33-00.